HC Wainwright Issues Pessimistic Forecast for IPSC Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Century Therapeutics to a loss of $0.12 per share from $0.11, while maintaining a “Buy” rating and $5.00 price target.
• Century Therapeutics reported a Q2 loss of $0.17 per share, missing the consensus estimate of a $0.11 loss. Analysts’ overall consensus rating is “Hold,” with an average price target of $4.75.
• IPSC shares opened at $1.92, well below the $2.19 50-day and $2.22 200-day moving averages; institutional investors own approximately 50.2% of the company.

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Century Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.12) per share for the quarter, down from their previous estimate of ($0.11). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Century Therapeutics' current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Century Therapeutics' FY2026 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.12) EPS and FY2027 earnings at ($0.47) EPS.

Several other research firms have also weighed in on IPSC. Weiss Ratings restated a "sell (d-)" rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Mizuho assumed coverage on shares of Century Therapeutics in a research note on Wednesday, May 27th. They issued an "outperform" rating and a $8.00 target price for the company. Finally, Wall Street Zen cut Century Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 27th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Century Therapeutics presently has an average rating of "Hold" and an average price target of $4.75.

Century Therapeutics Price Performance

Shares of IPSC stock opened at $1.92 on Monday. The company has a fifty day moving average price of $2.19 and a two-hundred day moving average price of $2.22. Century Therapeutics has a one year low of $0.43 and a one year high of $3.04. The stock has a market cap of $346.27 million, a P/E ratio of -2.06 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.06).

Institutional Trading of Century Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. bought a new position in Century Therapeutics in the 2nd quarter valued at about $25,000. Bank of New York Mellon Corp bought a new stake in shares of Century Therapeutics during the first quarter worth approximately $29,000. Qube Research & Technologies Ltd acquired a new position in shares of Century Therapeutics in the second quarter valued at approximately $38,000. Quadrant Private Wealth Management LLC grew its position in shares of Century Therapeutics by 31.0% in the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company's stock valued at $45,000 after purchasing an additional 4,736 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Century Therapeutics during the second quarter worth approximately $51,000. Institutional investors own 50.20% of the company's stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source